PYRIDOXINE-dependent epilepsy (PDE): An observational study of neonatal cases on the role of pyridoxine in patients treated with standard anti-seizure medications

Seizure. 2024 May:118:156-163. doi: 10.1016/j.seizure.2024.04.012. Epub 2024 May 11.

Abstract

Background: The main objective of this study was to evaluate the neurological consequences of delayed pyridoxine administration in patients diagnosed with Pyridoxin Dependent Epilepsies (PDE).

Materials and methods: We reviewed 29 articles, comprising 52 genetically diagnosed PDE cases, ensuring data homogeneity. Three additional cases were included from the General Pediatric Operative Unit of San Marco Hospital. Data collection considered factors like age at the first seizure's onset, EEG reports, genetic analyses, and more. Based on the response to first-line antiseizure medications, patients were categorized into four distinct groups. Follow-up evaluations employed various scales to ascertain neurological, cognitive, and psychomotor developments.

Results: Our study includes 55 patients (28 males and 27 females), among whom 15 were excluded for the lack of follow-up data. 21 patients were categorized as "Responder with Relapse", 11 as "Resistant", 6 as "Pyridoxine First Approach", and 2 as "Responders". The neurological outcome revealed 37,5 % with no neurological effects, 37,5 % showed complications in two developmental areas, 15 % in one, and 10 % in all areas. The statistical analysis highlighted a positive correlation between the time elapsed from the administration of pyridoxine after the first seizure and worse neurological outcomes. On the other hand, a significant association was found between an extended latency period (that is, the time that elapsed between the onset of the first seizure and its recurrence) and worse neurological outcomes in patients who received an unfavorable score on the neurological evaluation noted in a subsequent follow-up.

Conclusions: The study highlights the importance of early recognition and intervention in PDE. Existing medical protocols frequently overlook the timely diagnosis of PDE. Immediate administration of pyridoxine, guided by a swift diagnosis in the presence of typical symptoms, might improve long-term neurological outcomes, and further studies should evaluate the outcome of PDE neonates promptly treated with Pyridoxine.

Keywords: Anti-Seizure Medication (ASM); Anticonvulsant therapy; Latency period; Neonatal seizures; Neurological outcomes; Pyridoxine-Dependent Epilepsy (PDE).

Publication types

  • Observational Study

MeSH terms

  • Anticonvulsants* / administration & dosage
  • Epilepsy* / diagnosis
  • Epilepsy* / drug therapy
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Pyridoxine* / administration & dosage
  • Pyridoxine* / therapeutic use
  • Vitamin B Complex / administration & dosage

Substances

  • Pyridoxine
  • Anticonvulsants
  • Vitamin B Complex

Supplementary concepts

  • Pyridoxine-dependent epilepsy